Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 97

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 97
---
Litigation From time to time the Company may become a party to litigation in the normal course of business. As of December 31, 2024, there were no legal matters that management believes would have a material effect on the Company’s financial position or results of operations.

Note 12 - Income Taxes The components of earnings before income taxes for the years ended December 31, 2024 and 2023 were as follows:                  For the Years Ended December 31, Income (loss) before income taxes 2024  2023        Domestic  (10,434,147)  (8,466,950)Foreign  (1,073,700)  (1,593,300)Total income (loss) before income taxes $(11,507,947) $(10,060,250)

 F-16 

Income tax provision (benefit) consists of the following for the years ended December 31, 2024 and 2023: Income tax provision (benefit):  For the Years Ended December 31, Current 2024  2023 Federal   -   - State  -   - Foreign  -   - Total Current  -   - Deferred        Federal  -   - State   -   - Foreign   -   - Total Deferred  -   -          Total income tax provision (benefit) $-  $-  A reconciliation of the income tax provision (benefit) by applying the statutory United States federal income tax rate to income (loss) before income taxes is as follows: Rate Reconciliation For the Years EndedDecember 31,     2024    2023   Expected tax at statutory rates $(2,416,700 )  21% $(2,099,400 )  21%Permanent Differences $(157,900 )  1%  (83,000 )  1%State Income Tax, Net of Federal benefit $(822,500 )  7%  (448,100 )  4%State Rate Change-Federal Impact $(42,300)  0%  -   0%State Rate Change Adjustment $201,300   -2%  -   0